CancerDrs

Lung Cancer clinical trials in Rhode Island

11 actively recruiting lung cancer trials at 2 sites across Rhode Island.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Rhode Island:
  • Rhode Island Hospital — Providence, Rhode Island
  • Roger Williams Medical Center — Providence, Rhode Island
  • Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Rhode Island:
  • Local Institution - 007-960 — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Rhode Island:
  • Lifespan Cancer Institute — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

Sponsor: AstraZeneca
NCT ID: NCT05797168
Sites in Rhode Island:
  • Research Site — Providence, Rhode Island
  • Research Site — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

Sponsor: AstraZeneca
NCT ID: NCT06996782
Sites in Rhode Island:
  • Research Site — Providence, Rhode Island
  • Research Site — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the P…

Sponsor: 7 Hills Pharma, LLC
NCT ID: NCT06362369
Sites in Rhode Island:
  • Brown University Health Cancer Institute — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

This single-arm phase 2 study will enroll patients with resectable and operable stage IB - III non-small cell lung cancer and treat them with pre-operative ipilimumab + nivolumab plus low-dose stereotactic body radiation therapy (SBRT) del…

Sponsor: Brown University
NCT ID: NCT04933903
Sites in Rhode Island:
  • Rhode Island Hospital — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have…

Sponsor: Pfizer
NCT ID: NCT06447662
Sites in Rhode Island:
  • Rhode Island Hospital — Providence, Rhode Island
  • Miriam Hospital — Providence, Rhode Island
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Rhode Island:
  • Providence Veterans Administration Hospital — Providence, Rhode Island
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15